BofA/Merrill Lynch Downgrades Achillion Pharmaceuticals (ACHN) Two-Notches to Underperform
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Buy to Underperform.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $11.57 yesterday.
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $11.57 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation
- Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
- BofA says used equipment values remain stable in July
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
